<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200623047903N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-07-25</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Leech Therapy and Dry cupping on Polycystic Ovary Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Effect  Of Leech therapy and Dry cupping with Contraceptives LD on Improvement of Menstrual Complaints in Women with Polycystic Ovary Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49170</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For sampling, first each qualified person is selected to enter the study  and Then the samples will be placed in the available method based on 4 blocks and random allocation in each of the two intervention groups (intervention) A or (control) B.
4 blocks will be used for sampling(AABB, ABAB, BBAA, BABA, ABBA,BAAB), Blinding description: In this study each questionnaire will be marked with the letters A (intervention group) and B (control group). People who do statistical work and analysis of data are blind to each participant than the intervention 
provided in this way, the person does not know which questionnaire is related to which intervention.After explaining the research to the research units and obtaining informed written consent based on random allocation, they will be placed in two groups of intervention and control
4 blocks will be used for sampling(AABB, ABAB, BBAA, BABA, ABBA,BAAB).</study_design>
      <phase>3</phase>
      <hc_freetext>Polycystic Ovary Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  In this group, Leech therapy and Dry cupping will be Performed once a week after the end of Menstrual Bleeding until the Start of the next Menstrual Period. At first Place Leeches from the Farthest Point to the Uterus,That is on the Ankle and then on the Waist an Uterus. Dry cupping with Leech Therapy will be  Placed around the Navel and in the Back (around the Spine).This will be done for two months and people are followed up for 3 months. Intervention 2: Control group: This group is treated with  Low dose (LD) pills with a combination of 0.03 mg of Ethinyl Estradiol and 0.15 mg of Levonorgestrel.It should be taken daily and at a specific time by the Person for 21 days from the Beginning of Menstruation and then the pill should be Stopped for 7 day and another pack should be started again.This will continue for two Consecutive Cycles.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Participants Information is Confidential</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ainaz Khodaverdian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 79, Ranjbar Ave., West Taleghani</address>
        <city>Bojnourd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9414844363</zip>
        <telephone>+98 58 3222 3280</telephone>
        <email>ainazkvn@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Roghaieh Rahmany Beilandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 79, Ranjbar Ave., West Taleghani</address>
        <city>Bojnourd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9414844363</zip>
        <telephone>+98 58 3222 3280</telephone>
        <email>roghaiehrahmany@yahoo.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The Polycystic Ovaries based on the individual's satatement
Having Written and oral consent to participate in the study
Age range of 18 to 40
Having reading and writing Literacy
Body mass index Between 18.5 to 24.9
Lack of drug use
No having chronic physical disease
They did not Receive any Treatment for Polycystic Ovaries for 6 Months ago
Failing to use hormonal drugs during the study
Do not Take Hormonal Medications During the Study
Patients with Stable Medical Condition
Not Pregnant
No Breastfeeding
People with Oligomenorrhea</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Individual Intolerance to Leeches or  Dry Cupping or LD</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  In this group, Leech therapy and Dry cupping will be Performed once a week after the end of Menstrual Bleeding until the Start of the next Menstrual Period. At first Place Leeches from the Farthest Point to the Uterus,That is on the Ankle and then on the Waist an Uterus. Dry cupping with Leech Therapy will be  Placed around the Navel and in the Back (around the Spine).This will be done for two months and people are followed up for 3 months</i_keyword>
      <i_keyword>Control group: This group is treated with  Low dose (LD) pills with a combination of 0.03 mg of Ethinyl Estradiol and 0.15 mg of Levonorgestrel.It should be taken daily and at a specific time by the Person for 21 days from the Beginning of Menstruation and then the pill should be Stopped for 7 day and another pack should be started again.This will continue for two Consecutive Cycles</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Duration of the Menstrual cycle. Timepoint: Before the Intervention, 1 Month, 2 and 3 Months after the Intervention. Method of measurement: A Researcher-made Questionnaire and Calendar.</prim_outcome>
      <prim_outcome>Menstrual Bleeding Volume. Timepoint: Before the Intervention, 1 Month, 2 and 3 Months after the Intervention. Method of measurement: Blood Visual Assessment Questionnaire.</prim_outcome>
      <prim_outcome>The Severity of Menstrual Cramps. Timepoint: Before the Intervention, 1 Month, 2 and 3 Months after the Intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Satisfaction with Treatment. Timepoint: After the Intervention. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Complications. Timepoint: After the Intervention. Method of measurement: Check list.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-17</approval_date>
        <contact_name>Ethics committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>No. 79, Ranjbar Ave., West Taleghani Bojnourd North Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
